

**CLINICAL EXPERIENCE OF TYROSINE-KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA**

B. SANCHEZ PASCUAL<sup>1</sup>, I. SALVADOR LLANA<sup>1</sup>, C. SANZ SANCHEZ<sup>1</sup>, M. PRADA BOU<sup>1</sup>, S. HERRERA CARRANZA<sup>1</sup>, M.D.P. MARTINEZ BARRANCO<sup>2</sup>, E. ZHAN ZOU<sup>1</sup>, P. SANMARTIN FENOLLERA<sup>1</sup>, M. PEREZ ENCINAS<sup>1</sup>.  
<sup>1</sup>HOSPITAL UNIVERSITARIO FUNDACION ALCORCON, PHARMACY, ALCORCON, SPAIN. <sup>2</sup>HOSPITAL UNIVERSITARIO FUNDACION ALCORCON, HEMATOLOGY, ALCORCON, SPAIN.  
 Contact data: belen.sanchez.pascual@salud.madrid.org


**BACKGROUND AND IMPORTANCE**

Tyrosine-kinase inhibitors (TKIs) have shown to be effective in chronic myeloid leukemia (CML) treatment. Recent clinical trials show selected patients with deep molecular response (DMR) can safely discontinue treatment.

**AIM AND OBJECTIVES**

Describing clinical experience of discontinuing treatment with TKIs in CML patients.

**MATERIAL AND METHODS**




Retrospective observational study → analyzed TKIs discontinuation and maintenance of mayor molecular response (MMR) after discontinuation in all CML patients treated at our center from the moment they started TKIs until September 2023.

Variables		
Age	Gender	TKI
TKI start date	Response	DMR achieving date
TKI switch before discontinuation and cause	Discontinuation date	Withdrawal síndrome (WS)
WS treatment	Restart date and TKI	Last consultation date

Discontinuation protocol stipulates patients must have been treated for five (1<sup>st</sup> generation TKIs) or three (2<sup>nd</sup> generation TKIs) years and must have achieved 2 years of DMR (molecular response (MR)=4 or greater). After discontinuation they have monthly monitoring visits for 6 months (period when most patients lose MMR), afterwards controls are spaced out over time. If patients lose MMR (MR=3) treatment should restart.

**RESULTS**



**CONCLUSION AND RELEVANCE**

Our results are in line with current literature showing controlled discontinuation is a viable and potentially long-term option. Discontinuation is already part of the standard of care in selected patients since it's cost-effective, representing savings for Healthcare System and improving patient's life quality.

